• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Essential CNS Drug Development

Essential CNS Drug Development

9780521766067
497,64 zł
447,87 zł Zniżka 49,77 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 447,87 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.
Szczegóły produktu
80777
9780521766067
9780521766067

Opis

Rok wydania
2012
Numer wydania
1
Oprawa
twarda
Liczba stron
215
Wymiary (mm)
161.00 x 240.00
Waga (g)
520
  • Preface; 1. History of CNS drug development Sheldon H. Preskorn; 2. Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J. Cross and Frank D. Yocca; 4. Phase I trials:: from traditional to newer approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5. Phase II development and the path to personalized medicine in CNS disease Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development - Phase III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs; 8. Clinical trials management at company level Nuala Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10. Medical writing for CNS indications Ginette Nachman; 11. Dissemination of clinical trial information:: multiple audiences, multiple formats Leslie Citrome; 12. The importance of treating cognition in schizophrenia and other severe mental illnesses:: background, strategies, and findings to date Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive technologies to drive innovation in CNS clinical drug development Penny Randall, Judith Dunn and Amir Kalali; Index.
Komentarze (0)